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Background: Cry j 2 and Cha o 2 are major allergens in Japanese cedar (Cryptomeria japonica; CJ) and
Japanese cypress (Chamaecyparis obtusa; CO) pollen, respectively. Here, we assessed the epitopes related
to the cross-reactivity between Cry j 2 and Cha o 2 using in vitro analyses.
Methods: Peptides were synthesized based on Cry j 2 sequential epitopes and relevant Cha o 2 amino
acid sequences. Four representative monoclonal antibodies (mAbs) against Cry j 2 were used according to
their epitope recognitions. Serum samples were collected from 31 patients with CJ pollinosis. To
investigate cross-reactivity between Cry j 2 and Cha o 2, ELISA and inhibition ELISA were performed with
mAbs and sera from patients with CJ pollinosis.
Results: Two of four mAbs had reactivity to both Cry j 2 and Cha o 2. Of these two mAbs, one mAb (T27)
recognized the amino acid sequence 169KVVNGRTV176 on Cha o 2. This is related to the core epitope
169KWVNGREI176 on Cry j 2, which is an important IgE epitope. In addition, we found that these
correlative sequences and puriﬁed allergens showed cross-reactivity between Cry j 2 and Cha o 2 in IgE
of CJ patients.
Conclusions: We demonstrated the importance of 169KVVNGRTV176 in Cha o 2 for cross-reactivity with
the Cry j 2 epitope 169KWVNGREI176, which plays an important role in allergenicity in CJ pollinosis. Our
results are useful for the development of safer and more efﬁcient therapeutic strategies for the treatment
of CJ and CO pollen allergies.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Seasonal allergic diseases including allergic rhinitis and asthma
occur worldwide, particularly in developed countries. Pollinosis is a
commonly-noted seasonal allergic disease induced by pollen al-
lergens. The pollinosis induced by Japanese cedar (Cryptomeria
japonica; CJ) pollen is one of the most common allergic diseases in
Japan.1 According to a survey conducted in the central Hokuriku
area of Japan inMay and June of both 2006 and 2007, 36.7% of study
participants (566 of the 1540 subjects) had allergic rhinitis to CJMicrobiology, School of Vet-
nobe, Chuo-ku, Sagamihara,
uchi).
ety of Allergology.
rgology. Production and hosting by Elsepollen.2 Japanese cypress (Chamaecyparis obtusa; CO) pollen is one
of the most important aeroallergens relevant to allergic symptoms
in Japan.3 The social impact and economic loss related to pollinosis
are estimated to be tremendous because of the impaired perfor-
mance of the patients, often accompanied by a self-imposed ban on
leaving home.
Allergen cross-reactivity has been reported at the immuno-
chemical and clinical levels. The cloning and sequencing of allergen
genes have provided a better understanding of their cross-
reactivity. The ﬁrst evidence for the existence of clinically rele-
vant cross-reactive IgE antibodies was reported in pollen-food
cross-reactive allergens.4 Other cross-reactive allergenic systems
have been induced by aeroallergens and food antigens.5,6 Many
efforts have been made to correlate the serological cross-reactivity
with elicitation of symptoms in susceptible patients, because not all
cross-reactive IgE antibodies give rise to clinical signs. Therefore, itvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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than clinical cross-allergenicity.7
Three major allergens, named Cry j 1, Cry j 2, and Cry j 3, have
been isolated from CJ pollen. Cry j 1 was isolated as a 41e46 kDa
allergen with pectate lyase enzyme activity,8,9 whereas Cry j 2 is a
45 kDa allergenwith polymethylgalacturonase enzyme activity.10,11
Cry j 3 is a 27 kDa protein that has relatively high homology with
thaumatin-like proteins in the pathogenesis-related-5 family pro-
teins.12 On the other hand, Cha o 1 and Cha o 2 were identiﬁed as
major allergens of CO with a high degree of homology with Cry j 1
and Cry j 2, respectively.3,13,14 Amino acid sequence homology be-
tween major allergens from CJ and CO results in cross-allergenicity.
Cross-allergenicity is observed between CJ and CO pollen aller-
gens.15 In our previous studies, animal models of Japanese monkeys
and dogs sensitized to CJ pollen demonstrated IgE reactivity to CO
pollen.16,17 Cry j 2 was characterized as a major allergen in CJ
pollinosis,10 and more than 90% of patients (139/145 subjects) had
the anti-Cry j 2 IgE.18 It was demonstrated that the IgE antibody
levels to Cry j 2 and Cha o 2 were strongly correlated,14 suggesting
that there are one or more epitopes with high similarity between
Cry j 2 and Cha o 2.
Six sequential and one conformational epitopes on Cry j 2 were
identiﬁed in our previous studies.19,20 Conformational epitopes on
allergens play an important role in initiating human IgE-mediated
allergic reactions.21e23 In fact, the conformational epitopes on Cry
j 1 are considered dominant in IgE reactivity as compared to the
sequential epitopes.24 However, we suggested the importance of
sequential epitopes on Cry j 2, especially 169KWVNGREI176, for
allergenicity at variance with other well-known allergens.20 To our
knowledge, it has yet to be demonstrated whether monoclonal
antibodies (mAbs) and patients' IgE to sequential epitopes on Cry j
2 can cross-react with the relevant epitopes on Cha o 2. This is the
ﬁrst report to indicate the cross-reactivity between sequential
epitopes on Cry j 2 and relevant sequences on Cha o 2 by mAbs and
patients' IgE. Here, we also analyze the cross-reactivity between the
Cry j 2 core epitope, 169KWVNGREI176, reported in our previous
studies19 and the related epitope on Cha o 2 by inhibition ELISA.We
used 169KWVNGREI176 because it was the only core epitope re-
ported in previous studies, and it is known to be a major epitope
recognized by patients' IgE.Table 1
Synthetic peptides and allergenic similarities between Cry j 2 linear epitopes (upper
sequences) and relevant Cha o 2 amino acid sequences (lower sequences).
The core determinant of P1-1 is shown in bold.
y Peptide numbers shown in brackets were linked to the study of Tamura et al.19
z Amino acid positions were described as complete sequences.
x The mAb reactivity to each peptide was determined in our previous study.20Methods
Antigens and mAbs
Cry j 2 in CJ pollen and Cha o 2 in CO pollen were puriﬁed as
previously described.10,14 Table 1 shows six peptides that were
synthesized based on Cry j 2 sequential epitopes recognized by
mAbs for Cry j 2 and relevant Cha o 2 amino acid sequences
(Hokkaido System Science Co., Ltd., Sapporo, Japan). We also syn-
thesized the core epitope on Cry j 2 (169KWVNGREI176) and the
relevant Cha o 2 amino acid sequence (169KVVNGRTV176). Four
representative mAbs for Cry j 2 (S1, T27, 9E7, and J2A01) were used
according to their epitope recognitions.20
Subjects
Informed consent was obtained from all subjects. The study
protocol was approved by the ethical committee at the Jikei
University School of Medicine. Serum samples were collected
from 31 patients with CJ pollinosis. The patients were selected
based on clinical symptoms of seasonal allergic rhinitis and
positive CAP (Phadia AB, Uppsala, Sweden) to CJ pollen. Their
IgE were preliminarily conﬁrmed to react with Cry j 2. To
determine the cut-off value, serum samples obtained from 10
non-allergic subjects, who had been previously conﬁrmed as
negative for the crude pollen allergen were used as negative
controls.
Colorimetric ELISA for Cry j 2, Cha o 2, and synthetic peptides with
mAbs
As previously described, the reactions of the mAbs were
measured using a colorimetric ELISA.19 Brieﬂy, Cry j 2, Cha o 2
(1 mg/ml), P1-1, P1-2, P3-1, and P3-2 (10 mg/ml) were immobilized
in the wells of a microplate (F96 Maxisorp® NUNC-Immuno™
Plate, ThermoFisher Scientiﬁc, Waltham, MA, USA) overnight at
4C. The microplate was then washed with phosphate-buffered
saline containing 0.05% Tween 20 (PBST) and incubated with
biotin-labeled mAbs (1 mg/ml) for 1 h at room temperature. Next,
streptavidin-peroxidase polymer (SigmaeAldrich, MO, USA) was
added to the wells. After a 1 h incubation period at room tem-
perature, a substrate solution of o-phenylenediamine dihydro-
chloride was added. After the enzyme reaction was terminated
with 2 M H2SO4, the optical density (OD) was measured using a
multi-mode microplate reader (Powerscan MX, DS Pharma
Biomedical, Osaka, Japan).
Colorimetric ELISA inhibition for Cry j 2 and Cha o 2 epitopes with
mAbs
It was difﬁcult to immobilize short peptides on the wells of the
microplate. Thus, to evaluate the reactivity of the T27 mAb with
169KWVNGREI176 (Cry j 2 core epitope) and 169KVVNGRTV176
(relevant sequence within Cha o 2), an inhibition ELISA was con-
ducted using these synthetic peptides as inhibitors.25 Brieﬂy, P1-1
and P1-2 (10 mg/ml) were immobilized in the wells of a micro-
plate overnight at 4C. The synthetic peptide inhibitors (ﬁnal con-
centrations, 0e100 mg/ml) were incubated with equal volumes of
T27 mAb (ﬁnal concentration, 10 ng/ml) for 1 h at room tempera-
ture. Subsequent procedures were the same as described above.
The inhibition ratio (%) was calculated as follows:

1 OD in presence of inhibitor
OD in absence of inhibitor

 100
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As previously described, speciﬁc IgE against synthetic peptides
were measured in the sera of patients using ﬂuorometric ELISA.20
Brieﬂy, synthetic peptides (20 mg/ml) were immobilized in the
wells of a microplate (FLUOTRAC™ 600, Greiner Bio-One GmbH,
Frickenhausen, Germany) overnight at 4C. The microplate was
then washed with PBST buffer and incubated with diluted (1:10)
serum samples for 3 h at room temperature. The plates were
washed, and anti-human IgE antibodies conjugated to b-D-galac-
tosidase (diluted 1:10; Phadia AB) were added to each well. The
enzyme reaction substrate, 0.2 mM 4-methylumbelliferyl-b-D-
galactoside (SigmaeAldrich) was added to the wells, and the plates
were incubated at 37C for 2 h. After quenching the reaction,
ﬂuorescence units (FU) were measured using a multi-mode
microplate reader. Cut-off values were determined using sera
from subjects without pollinosis as negative controls.
Fluorometric ELISA inhibition for Cry j 2 and Cha o 2 with human IgE
To evaluate cross-reactivity between Cry j 2 and Cha o 2, we
used a ﬂuorometric ELISA inhibition for Cry j 2 and Cha o 2 with
human IgE.20 Brieﬂy, Cry j 2 or Cha o 2 (0.5 mg/ml) were immobi-
lized in the wells of a microplate (FLUOTRAC™ 600) overnight at
4C. Cry j 2 or Cha o 2 inhibitors (ﬁnal concentrations, 0e10 mg/ml)
were incubated with equal volumes of human sera (ﬁnal dilution,
1:50) for 3 h at room temperature. Themicroplatewas thenwashed
with PBST buffer and incubated with diluted (1:10) serum samples
for 3 h at room temperature. Subsequent procedures were the same
as described above.Fig. 1. Reactivity of Cry j 2 mAbs. Cry j 2 and Cha o 2 were immobilized on a microplate
(A). The peptides P1-1, P1-2, P3-1, and P3-2 were coated on a microplate (B). Biotin-
labeled S1, T27, 9E7, and J2A01 mAbs were reacted with each peptide. The binding
activity of each mAb is expressed as optical density (OD). Experiments were performed
in triplicate, and data are expressed as mean values ± SD from triplicate de-
terminations. S1 and J2A01 mAbs share the same epitopes as bound by J2A07 and
J2A03, respectively.14Fluorometric ELISA inhibition for Cry j 2 and Cha o 2 peptides with
human IgE
It was difﬁcult to immobilize short peptides on the wells of the
microplate. Therefore, to evaluate the reactivity of human IgE to
169KWVNGREI176 (Cry j 2 core epitope) and 169KVVNGRTV176
(relevant sequence within Cha o 2), an inhibition ELISA was
conducted using these synthetic peptides as inhibitors. Brieﬂy,
P1-1 and P1-2 (10 mg/ml) were immobilized in the wells of a
microplate (Nunc® Immobilizer™ Amino Plate, ThermoFisher
Scientiﬁc) overnight at 4C. The synthetic peptide inhibitors (ﬁnal
concentrations, 0e100 mg/ml) were incubated with equal vol-
umes of human sera (ﬁnal dilution, 1:100) for 3 h at room tem-
perature. Subsequent procedures were performed as described
above.
Results
Reactivity of Cry j 2 mAbs to Cry j 2 and Cha o 2 peptides
To examine the reactivity of four mAbs to Cry j 2 and Cha o 2
peptides, the binding of mAbs to each allergen was measured by
ELISA. We found that T27 and J2A01mAbs reacted with both Cry j 2
and Cha o 2 (Fig. 1A). These twomAbs have cross-reactivity to Cha o
2. However, the S1 mAb against a conformational epitope and 9E7
mAb against P2-1 reacted with Cry j 2, but not with Cha o 2
(Fig. 1A). These two mAbs have Cry j 2-speciﬁc binding. T27 mAb
reactedwith both Cry j 2-related peptide (P1-1) and Cha o 2-relatedFig. 2. Colorimetric ELISA inhibition using mAb against epitopes. Cry j 2 (A) or Cha o 2
(B) peptides (P1-1 or P1-2) were immobilized in the wells of a microplate. The Cry j 2
peptide 169KWVNGREI176 (closed circles) and the Cha o 2 peptide 169KVVNGRTV176
(closed squares) were incubated as inhibitors with equal volumes of T27 mAb. Unre-
lated peptide P3-1 was used as a negative control (closed triangles). Inhibition ratios
were calculated as a percentage in the presence of homozygous or heterozygous in-
hibitors. Experiments were performed in triplicate, and data are expressed as mean
values ± SD from triplicate determinations.
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related peptide (P3-1) and Cha o 2-related peptide (P3-2) (Fig. 1B).
Cross-reactivity of T27 mAb between Cry j 2 and Cha o 2 peptides
To further evaluate the mAb reactivity with Cry j 2 and Cha o 2
peptides, we conducted ELISA inhibition using these peptides. The
T27 mAb binding to Cry j 2 peptide (P1-1) was concentration-
dependently inhibited by both 169KWVNGREI176 (Cry j 2 core
epitope peptide) and 169KVVNGRTV176 (relevant Cha o 2 peptide)
(Fig. 2A). In addition, the binding of this mAb to Cha o 2 peptide
(P1-2) was inhibited by both Cry j 2 and Cha o 2 peptides (Fig. 2B).
We found that this mAb exhibits cross-reactivity between the Cry j
2 core epitope in P1-1 and the relevant Cha o 2 peptide. In T27 mAb
for Cry j 2, the inhibitory efﬁciency of the Cry j 2 peptide
169KWVNGREI176 was higher than that of the Cha o 2 peptide
169KVVNGRTV176.
Reactivity of human IgE to Cry j 2 and Cha o 2 peptides in patients
with Cry j 2-speciﬁc IgE
To evaluate IgE reactivity to Cry j 2 and Cha o 2 peptides, speciﬁc
IgE to these peptides were measured in the sera of 31 human pa-
tients with Cry j 2-speciﬁc IgE. We summarize the FU titers of pa-
tients' IgE to each peptide in Table 2. The cut-off values used for
each peptide were set as the mean value þ 3SD of 10 negative
controls. Of 31 patients, 10 patients had speciﬁc IgE to both P1-1
and P1-2, 13 patients had speciﬁc IgE to only P1-1, and 8 patients
had no speciﬁc IgE to either peptide (Fig. 3A). Of 31 patients, 5
patients had speciﬁc IgE to both P2-1 and P2-2, 7 patients had
speciﬁc IgE to only P2-1, 2 patients had speciﬁc IgE to only P2-2, and
17 patients had no speciﬁc IgE to either peptide (Fig. 3B). Of 31
patients, 10 patients had speciﬁc IgE to both P3-1 and P3-2, 10
patients had speciﬁc IgE to only P3-1, 1 patient had speciﬁc IgE to
only P3-2, and 10 patients had no speciﬁc IgE to either peptide
(Fig. 3C). Speciﬁc IgE to Cry j 2 showed the strongest reactivity to
P1-1 and P1-2 among these peptides.
Cross-reactivity of human IgE between Cry j 2 and Cha o 2
In a representative patient with speciﬁc IgE to both P1-1 and P1-
2 (Fig. 4A), allergenic cross-reactivity of Cry j 2 and Cha o 2 was
investigated by ELISA inhibition. Incubation of the serum with the
homologous Cry j 2 or Cha o 2 greatly inhibited binding (Fig. 4B).
IgE binding to the solid-phase Cha o 2 was greatly inhibited by Cry j
2, but IgE binding to the solid-phase Cry j 2 was not greatly
inhibited by Cha o 2 (Fig. 4B). We found cross-reactivity between
Cry j 2 and Cha o 2, and Cry j 2 has a trend of greater inhibition than
Cha o 2.
Cross-reactivity of human IgE between Cry j 2 and Cha o 2 peptides
To evaluate IgE cross-reactivity with the Cry j 2 peptide
169KWVNGREI176 in P1-1 and the Cha o 2 peptide 169KVVNGRTV176Table 2
Summarized results of total IgE ﬂuorescence units of 31 patients.
Coated peptide Minimum Maximum Median
P1-1 0 31,026 916
P1-2 11 10,242 79
P2-1 1 293 88
P2-2 0 399 62
P3-1 0 822 94
P3-2 0 1268 41
Fig. 3. IgE reactivity between Cry j 2 and Cha o 2 synthetic peptides. Binding activity is
expressed in ﬂuorescence units (FU). The x-axis is for Cry j 2-related peptides and the
y-axis is for Cha o 2-related peptides. Serum samples from 31 patients were used to
examine their IgE reactivity against P1-1 and P1-2 (A), against P2-1 and P2-2 (B), and
against P3-1 and P3-2 (C). The cut-off values (dashed lines) were determined as the
mean þ 3SD FU in negative controls. Open circles in (A) indicate representative pa-
tients in Fig. 4. Experiments were repeated at least three times.
Fig. 4. Reactivity and inhibition ratios of IgE binding in representative patients. Binding activities of IgE from representative patients with double-positive reactivity to P1-1 and P1-
2 (A, patient no. 1) and single positive reactivity to P1-1 (D, patient no. 2) are expressed in ﬂuorescence units (FU). The dashed line represents the cut-off value which was
determined as the mean þ 3SD FU in negative controls. The cut-off values are 85.9 FU for the Cry j 2 peptide P1-1 and 110.0 FU for the Cha o 2 peptide P1-2. The inhibitory effects of
the Cry j 2 (closed circles) and Cha o 2 (closed squares) on IgE binding to Cry j 2 and Cha o 2 were observed in patient no. 1 (B). The inhibitory effects of the Cry j 2 peptide
169KWVNGREI176 (closed circles) and Cha o 2 peptide 169KVVNGRTV176 (closed squares) on IgE binding to P1-1 and P1-2 were observed in patient no. 1 (C). In contrast, the inhibitory
effect of Cha o 2 peptide 169KVVNGRTV176 was not observed in patient no. 2 (D). Inhibition ratios were calculated as a percentage under the presence of homozygous or het-
erozygous inhibitors. Experiments were performed in triplicate, and data are expressed as mean values ± SD from triplicate determinations.
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human IgE. The binding of IgE from a representative patient was
strongly inhibited by 169KWVNGREI176 peptide and moderately
inhibited by 169KVVNGRTV176 peptide (Fig. 4C). We found that the
IgE from a representative patient displayed cross-reactivity be-
tween the Cry j 2 core epitope in P1-1 and the relevant Cha o 2
peptide. In contrast, an inhibitory effect of 169KWVNGREI176 was
observed in a patient with single positive reactivity to P1-1, but this
was not the case with 169KVVNGRTV176 (Fig. 4D).
Discussion
Allergic symptoms such as rhinoconjunctivitis are induced by CJ
and CO pollen allergens. The major causal allergen of pollinosis in
Japan is CJ pollen because of the abundant pollination and wide-
spread distribution of CJ. CO is the secondmost common pollinosis-
inducing conifer in Japan. Cry j 2 is one of the major allergens in CJ
pollen, and its homologue is isolated from CO as Cha o 2.14 IgE levels
between Cry j 2 and Cha o 2 were highly correlated in the sera of
patients with pollinosis.14 Moreover, bioinformatics tools such as
the BLASTP (Protein Basic Local Alignment Search Tool; http://
www.ncbi.nih.gov/blast) and SDAP (Structural Database of Aller-
genic Proteins; http://fermi.utmb.edu/SDAP/)26,27 also suggest the
existence of cross-reactive epitopes between Cry j 2 and Cha o 2.
Until now, however, the contributing epitopes had not been iden-
tiﬁed on Cry j 2 and Cha o 2.
The T27 mAb reacted to P1-1 of Cry j 2 and P1-2 of Cha o 2
(Fig. 1B), and both the Cry j 2 core epitope peptide 169KWVNGREI176
and the Cha o 2 relevant peptide 169KVVNGRTV176 efﬁciently
inhibited the binding of T27 mAb to P1-1 and P1-2 (Fig. 2).
169KWVNGREI176 and 169KVVNGRTV176 also blocked the binding of
IgE from the patient with double-positive IgE to P1-1 and P1-2
(Fig. 4C). These results indicate that the 169KVVNGRTV176
sequence in Cha o 2 is cross-reactive with the Cry j 2 epitope
169KWVNGREI176 for mAb and patient IgE. This is another example
indicating that antibodies can not only bind to the original epitope
but also to sequences that may have a few different amino acids.
This raises the intriguing possibility of cross-reactivity to non-
homologous amino acids, which may have a large contribution to
allergic diseases. On the other hand, in a patient with single positive
reactivity to P1-1, the IgE binding to P1-1 was inhibited by
169KWVNGREI176, but not 169KVVNGRTV176. This result suggests the
presence of another core epitope which partially overlaps with
169KWVNGREI176.
As shown in Fig. 1B, the J2A01 mAb reacted to both the Cry j 2
peptide (P3-1) and the Cha o 2 peptide (P3-2). Therefore, we tried
to identify the core determinants for this antibody by using syn-
thetic peptides with 10e20 residues but failed to do so (data not
shown). This J2A01 mAb shares the same epitope as bound by
J2A03 mAb used in our previous study.14 In our previous study, it
was suggested that the core determinants result from discontin-
uous amino acids within the synthetic peptides.20 The present re-
sults may support the previous suggestion. The 9E7 mAb against
P2-1 did not cross-react with the Cha o 2 peptide (Fig. 1A). How-
ever, of the 31 patients, IgE from the sera of 5 patients reacted with
both P2-1 and P2-2 peptides, and there seemed to be a good cor-
relation between these peptides (Fig. 3B). Our results suggest that
the core determinant for the 9E7 mAb in P2-1 had fewer or no
overlaps with P2-2. We did not determine the core epitope of P2-1,
because we did not have a sufﬁcient volume of sera from patients
whose IgE reacted with this peptide. Further studies are needed to
identify the core sequences for J2A01 and 9E7 mAbs by in vitro
analysis.
We demonstrated IgE responses to Cry j 2 peptides in our pre-
vious studies,19,20 and the cross-reactivity between the sequenceepitopes on Cry j 2 and Cha o 2 in the present study. In addition to
Cry j 2 and Cha o 2, other group 2 conifer allergens are some of the
main pollen allergens: Jun a 2 for Juniperus ashei (Mountain ce-
dar),28 Jun o 2 (also known as Jun o 4) for Juniperus oxycedrus
(Prickly juniper),29 Tax d 2 for Taxodium distichum (Bald cypress),
and Cup a 2 for Cupressus arizonica (Arizona cypress). They belong
to the family Cupressaceae and cause pollinosis in areas such as
North America30,31 and the Mediterranean region.32,33 In addition
to in vitro analyses, we suggest the possibility that cross-reactive
epitopes exist among some group 2 conifer allergens by in silico
analyses (data not shown). The in silico analysis also estimated that
170KTINGRTV177 for Jun a 2 [property distance index (PD) ¼ 6.55],
139KWINGREI146 for Tax d 2 (0.68), and 117KTINGRTV124 for Cup a 2
(5.87) were epitopes relevant to the Cry j 2 epitope
169KWVNGREI176. The results suggest that cross-reactivity between
the Cry j 2 core epitope and the related Tax d 2 and Cup a 2, but not
Jun a 2, sequences, will be observed according to the threshold
proposed by Ivanciuc et al.,34 which may lie between 5 and 6.5.
Conversely, sera from patients with CJ pollinosis demonstrated
binding to Jun a 2,28 suggesting that epitopes rather than P1-1 are
important for cross-reactivity between Cry j 2 and Jun a 2. Our
ﬁndings provide useful information for the development of thera-
peutic strategies for pollinosis.
IgE antibodies to CJ have also been found in monkeys with
pollinosis19,24 and dogs with atopic dermatitis.35 Monkeys with CJ
pollinosis have symptoms similar to those of human patients. Dogs
live in the same environment as humans and naturally develop a
pruritic dermatitis that is extremely similar to human atopic
dermatitis. Moreover, monkeys16 and dogs17 sensitized to CJ pollen
were reported to have cross-reactive IgE to CO pollen. Although
allergenic cross-reactivity between Cry j 1 and Cha o 1 was
demonstrated in those studies, cross-reactivity between Cry j 2 and
Cha o 2 remains to be elucidated. Because of the remarkable sim-
ilarity with the human diseases, monkeys and dogs are considered
prime animal models for allergic diseases. Further in vivo studies
using such animal models will provide a better understanding of
cross-reactivity of CJ and CO.
In summary, we showed that the amino acid sequences in Cha o
2 cross-react with Cry j 2 epitopes at themAb and human IgE levels.
We also provided evidence of the importance of 169KVVNGRTV176
in Cha o 2 cross-reactivity with the Cry j 2 epitope 169KWVNGREI176,
which plays an important role in allergenicity in CJ pollinosis. In-
duction of blocking IgG4 that can recognize IgE epitopes is
responsible for clinically successful allergen-speciﬁc immuno-
therapy.36 Therefore, targeting epitopes related to cross-reactivity
may help in the development of immunotherapy against multiple
allergic diseases. Our results are useful for the development of safer
and more efﬁcient therapeutic strategies for treating CJ and CO
pollen allergies.
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